Other conditions decisions — 2024

The appeal seeking payment or reimbursement for the cost of medical services performed on November 24, 2020 by Aegis Sciences Corporation is dismissed as the benefit has been approved.

The Board denied the Veteran's appeal as the overpayment of $1,212.26 for additional compensation benefits due to a retroactive removal of his former spouse S., finding that the debt was proper and valid.

The Board has decided to remand the claims for beneficiary travel benefits on March 2, 2022, and April 15, 2022 due to lack of authorization for treatment.

The Veteran's gastroenteritis is rated at 30 percent since May 19, 2024. Prior to that date, the rating was noncompensable.

The Board has decided to remand the case due to a pre-decisional duty-to-assist error by the RO in not considering evidence indicating that the basis for the overpayment was erroneous and failing to address the effect of a March 2021 award action. The Veteran is seeking a waiver or partial waiver of an overpayment debt.

The Veteran's interstitial lung disease is being remanded due to a duty-to-assist error related to pulmonary function test results and the need for clarification on the proportion of impairment attributable to service-connected and non-service-connected conditions.

The Board has remanded the case due to a duty-to-assist error in the September 2017 VA examination, which did not provide a rationale for its opinion. The Veteran's lower back condition is related to service.

The Board has found that the appellant's entire period of service was a bar to VA benefits due to an other than honorable discharge. However, missing federal records indicate there may be additional periods of honorable service and further investigation is needed.

The Veteran's spouse P.W. was recognized as his dependent effective April 12, 2019, after he submitted a claim for additional dependency compensation within the one-year time limit due to good cause related to the COVID-19 pandemic.

The appeal for payment or reimbursement of non-VA medical services provided on March 13, 2020 is dismissed as the claim was administratively reviewed and approved.

The Veteran's VR&E benefits appeal is dismissed as he has achieved the goals outlined in his rehabilitation plan and was deemed rehabilitated to the point of employability on July 20, 2023.

The Board dismissed the appeal because the claim for a waiver of overpayment recoupment is moot as the Appellant's waiver request has already been granted.

The Board dismissed the appeal for service connection of urinary incontinence due to a violation of a claims processing rule, specifically because the Veteran filed another VA Form 10182 appealing the same issue from the January 2020 rating decision while already choosing a Board appeal for that issue.

The Veteran's ratings for right hip strain, limitation of flexion and impairment of thigh were restored to 20 percent effective January 16, 2020.

The Board has remanded the case due to a failure to provide a VA examination and because there was an error in not considering all available evidence, including the Veteran's statements about military sexual trauma during basic training.

The Board has determined that the claim for payment or reimbursement of non-VA medical treatment on September 22, 2020 is not clear and complete due to a lack of information regarding when the non-VA provider submitted the claim. The case is being remanded for further development.

The Board dismissed the appeal because it does not have jurisdiction to review the claim for payment of non-VA medical expenses incurred by the Veteran on March 16, 2020 under the VCCP.

The appeal is dismissed because the VA has already approved payment for non-VA medical services provided on September 1, 2020.

The Veteran's overpayment of VA pension benefits has been resolved and no longer exists, thus the appeal is dismissed.

The Board has dismissed the appeal as no case or controversy remains due to the withdrawal of representation and failure to contest the assigned effective dates for TDIU and DEA.